Single-dose psilocybin is beneficial in the short term for treatment-resistant depression

Clinical Question

For patients with treatment-resistant depression, is a single dose of psilocybin effective at improving symptoms?

Bottom line

At 3 weeks, a single 25-mg dose of psilocybin provided a clinically meaningful benefit for patients with treatment-resistant depression (NNT for remission = 5). However, the benefit was not well sustained at 12 weeks. Further study is needed to establish the optimal dose and frequency of treatment. 1b

Study design: Randomized controlled trial (double-blinded)

Funding: Industry

Setting: Outpatient (any)

Reviewer

Mark H. Ebell, MD, MS
Professor
University of Georgia
Athens, GA


Discuss this POEM


Comments

John W. Alvarez de Lorenzana

Psilocybin for TRD

Great to finally see some of the research on psychedelic assisted therapies showing up!

Anonymous

Psilocybin for depression

Disappointing results.

Anonymous

Careful creating more problems

Ketamine, and now psylobicin. These are short term solutions with no long-term vision for the complex problem that is depression. The medical field is already in big part to blame for the current opioid crisis in North America. This is how it starts. Prescribing these medications will stimulate a constant yearn for the temporary 'high' and relief of depression without addressing the real issues which include social circumstances, coping skills, underlying anxiety and biochemical imbalance. I am very sceptical.

Anonymous

psilocybin in treatment resistant depression

may be helpful but effects lasted 12 wks

Arup Kumar Dhara

Impact assessment

Very good